

SEP 10 1997



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

H20

David J. Levy, Ph.D.
Glaxo Wellcome, Inc.
Patent Counsel
Five Moore Drive
Research Triangle Park, NC 27709

Re: Patent Term Extension
Application for
U.S. Patent No. 4,883,812

Dear Mr. Levy:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 4,883,812 for a period of 1,347 days.

Telephone inquiries regarding this communication should be directed to the undersigned at (703)306-3159.

A handwritten signature in dark ink, appearing to read "Karin Tyson", written over a horizontal line.

Karin Tyson
Legal Advisor
Special Program Law Office
Office of the Deputy Assistant Commissioner
for Patent Policy and Projects

cc: Ronald L. Wilson, Director
Health Assessment Policy Staff
Office of Health Affairs (HPY-20)
Food and Drug Administration
5600 Fishers Lane, Room 15-22
Rockville, MD 20857

RE: FLOLAN®
FDA Docket No.: 95E-0419

kt

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE EXTENDING PATENT TERM
UNDER 35 U.S.C. § 156

PATENT NO. : 4,883,812
ISSUED : November 28, 1989
INVENTOR(S) : Salvador Moncada
PATENT OWNER : Glaxo Wellcome Inc.

This is to certify that there has been presented to the

COMMISSIONER OF PATENTS AND TRADEMARKS

an application under 35 U.S.C. § 156 for an extension of the patent term. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

1,347 days

from September 3, 2002, the original expiration date of the patent, with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the Patent and Trademark Office to be affixed this 5th day of September 1997.

Bruce A. Lehman

Bruce A. Lehman

Assistant Secretary of Commerce and
Commissioner of Patents and Trademarks